We bring decades of CGT experience to serving cancer patients in need.
01 / ABOUT CELLPEUTICS
Cellpeutics is a Shanghai-based, clinical-stage biotech company developing the next generation of oncolytic virus and T cell therapies against solid tumors. We are committed to making T cell immunotherapies accessible, affordable, and available to cancer patients.
02 / OUR SCIENCE
We are the first company to develop dual oncolytic virus and T cell therapies against solid tumors.
We use oncolytic viruses to reprogram tumors in vivo as transplanted organs or grafts, triggering allogeneic T cell responses on top of multiple anti-tumor mechanisms.
Oncolytic viruses are being developed as single agents or in combination with immune checkpoint inhibitors and T cell therapies.
Using an AI-powered lentivirus modification, we have developed a novel T cell reprogramming approach, in vivo TCR-T.
Under in vivo TCR-T, the treatment will be streamlined with the ultimate simplicity: no chemotherapy-based lymphodepletion, no HLA matching, and no ex vivo expansion.
TILs come from a patient’s tumor tissues and have the potential to recognize multiple targets. Our next-generation TILs are capable of expanding and homing to tumors in vivo.
03 / DEVELOPMENT PIPELINE
Scroll horizontally to view all development stages.
| Program | Indications | Preclinical | IIT | IND trials |
|---|---|---|---|---|
| OV101Oncolytic virus | Multiple solid tumors with peritoneal metastases, triple-negative breast cancer, and head and neck cancer | Completed | In progress | Planned |
| 820 TCR-TT-cell therapy | Esophageal, Gastric, and triple-negative breast cancers | Completed | In progress | Planned |
| TIL Tumor-infiltrating lymphocytes | Multiple solid tumors | Completed | In progress | Planned |
| OV201Oncolytic virus | Multiple solid tumors | Completed | Planned | Planned |
| 806 TCR-TT-cell therapy | Synovial sarcoma, melanoma and cholangiocarcinoma | Completed | Planned | Planned |
| In vivo TCR-TT-cell therapy | Multiple solid tumors | In progress | Planned | Planned |
IIT: investigator-initiated trial. IND: investigational new drug.
04 / RESEARCH REAGENTS
We specialize in developing mouse polyclonal antibodies for allergen research. We also offer custom antibody development for difficult targets and polyclonal production at scale.
Research reagents are for research use only. Not for diagnostic or therapeutic use.
Research targets
Mouse polyclonal antibodies
Mouse polyclonal antibodies
Whether you need a custom antibody or want to discuss bulk supply and distribution, share your target and requirements with our team.
RESEARCH & COLLABORATION
05 / LEADERSHIP
Our leaders have worked across academic research, cell therapy industry, and clinical practices.
Founder & CEO
A UCLA professor who trained with Steven A. Rosenberg, Dr. Zeng has nearly 30 years of experience in tumor T-cell immunology and clinical translation. His team completed a U.S. Phase I study of 800 TCR-T therapy in kidney cancer.
Co-founder & CTO
Dr. Liu has spent more than a decade developing cell therapies for commercial application in China. He designed a parallel dual-target CAR-T therapy and has worked on international licensing partnerships.
Senior VP, Clinical Development
Luo has nearly 20 years of experience in cell and gene therapy and clinical drug development. A former physician with a master’s degree in clinical medicine from Tongji Medical College, Luo has led clinical programs at multiple cell and gene therapy companies.
Head of Oncolytic Virus R&D
Professor Guo has studied oncolytic vaccinia viruses for cancer immunotherapy for more than two decades. His work includes participation in Phase I studies of dual-gene-deleted oncolytic viruses in solid tumors.
06 / GET IN TOUCH
Looking for a research reagent or exploring a development partnership? Tell us what you have in mind. Our team also welcomes inquiries about oncology consultation.
We’ll prepare an email draft for you. Review it in your email app, then send it to our team.